CNRS Université Paris-Sud 11


Sur ce site

Bâtiments 104 et 108
91405 Orsay Campus

+33 1 69 15 52 13
104 +33 1 69 15 50 08
108 +33 1 69 15 52 68
Mentions légales

Accueil > Séminaires > Séminaires passés > Seminaires de 2013 > Sandrine Lacombe (ISMO)

Nanomedicine and hadrontherapy

Sandrine Lacombe (ISMO)

Mardi 28 Mai 2013 14h salle de réunion Bat.108 1er étage

The main techniques used to treat cancer (surgery, chemotherapy, and radiotherapy) cause severe side effects to the patients due to strong damage and poisoning in the healthy tissues. The improvement of targeting and efficiency of the treatments is a challenge for future developments.
In this respect, Protontherapy and hadrontherapy, which use fast protons and carbon ions as ionizing particles, have specific advantages. The ballistic effect of the fast ions interacting with the biological matter (the Bragg peak) enhances the dose deposition into the tumor. It thus improves the preservation of the tissue sited behind. However the dose deposited at the entrance of the track is not negligible.
To improve the performances of proton/hadrontherapy, the group of S. Lacombe is developing a new strategy where nanoparticles (<3nm) are combined with fast ion irradiation [1]. A multiple-scale approach, from DNA molecule to living cells, is adopted by the group to quantify and to characterize the efficiency of potentially active nanodrugs. The group has shown for the first time that platinum and gadolinium nanoparticles amplify efficiently the radiation effects of fast ions. They have shown that the addition of nanoparticles enhances the induction of nanometric damages (>2-3 nm).

[1] Porcel, E., et al., Platinum nanoparticles : a promising material for future cancer therapy ? Nanotechnology, 2010. 21(8) : p. 7.
[2] Porcel, E., et al. Nano-Sensitization under gamma rays and fast ion radiation J. Phys. : Conf. Ser. 373, 012006 (2012).